ArticleMolecular pharmaceutics2026
Solubility of Incongruently Melting Active Pharmaceutical Ingredient Cocrystals: The Hydrochlorothiazide-Nicotinamide System.
Article in Molecular pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmaceutical cocrystallization is a promising strategy to enhance the solubility and bioavailability of hydrophobic active pharmaceutical ingredients (APIs). However, when API-coformer cocrystals exhibit incongruent melting, understanding and predicting their solubility in water becomes significantly more complex. In this work, a combined experimental and thermodynamic modeling approach is presented to investigate the API solubility enhancement in a ternary API-coformer-water system. Hydrochlorothiazide (HCT), a biopharmaceutics classification system (BCS) class IV diuretic, and nicotinamide (Nic), a generally recognized as safe (GRAS)-listed coformer, were selected as a representative system that forms an incongruently melting 1:1 cocrystal, which was confirmed experimentally using differential scanning calorimetry (DSC) and powder X-ray diffraction (PXRD). Binary solid-liquid equilibrium (SLE) data for the HCT-Nic, HCT-water, and Nic-water systems were experimentally measured at different temperatures. The nonrandom two-liquid (NRTL) model was then used to regress the binary interaction parameters from the binary SLE data. These parameters were then used to predict ternary SLE phase diagrams of the HCT-Nic-water system at 310.15 K, 330.15 K, and 350.15 K. The NRTL-modeled SLE diagrams revealed the key features of the ternary system, including the absence of cocrystal formation at 310.15 K and the emergence of a cocrystal phase region with incongruent dissolution behavior at elevated temperatures. The highest HCT solubility was obtained at the ternary API-rich eutectic composition, with a solubility enhancement factor (Φ) of 2.1-2.4 across the studied temperatures. In contrast, dissolving the 1:1 cocrystal directly in water yielded significantly lower solubility enhancements (Φ ≈ 1.0-1.3). These findings clearly demonstrate that selecting a binary HCT-Nic mixture that, upon dilution in water, reaches the eutectic composition in the ternary HCT-Nic-water system yields greater solubility enhancement than starting from the cocrystal composition. This study emphasizes the importance of thermodynamic modeling in understanding solubility behavior and guiding the rational design of cocrystal-based pharmaceutical formulations, especially for API-coformer systems exhibiting incongruent melting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.